# Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure

> **NCT00399269** · PHASE3 · COMPLETED · sponsor: **Cadila Pharnmaceuticals** · enrollment: 100 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** Recombinant Human Erythropoietin alpha

## Key facts

- **NCT ID:** NCT00399269
- **Lead sponsor:** Cadila Pharnmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** —
- **Final completion:** 2007-06
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2009-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399269, "Efficacy & Safety Study of Recombinant Human Erythropoietin -Alpha, in Patients With Anemia of Chronic Renal Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00399269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*